Linkdoc Technology (Beijing) Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Linkdoc Technology (Beijing) Co., Ltd. - overview
Established
2014
Location
Beijing, -, China
Primary Industry
Healthcare IT
About
LinkDoc Technology (Beijing) Co. , Ltd. was founded in 2014 and is headquartered in Beijing, China. The company was established with the mission of leveraging big data and artificial intelligence (AI) to improve healthcare outcomes, particularly in oncology.
The company’s early focus was on building structured clinical data platforms for oncology departments in tertiary hospitals. Over time, it expanded its services to include full-cycle data governance, AI-driven analytics, and digital therapeutics. LinkDoc has undergone several rounds of financing. It operates across multiple cities in China and collaborates with over 300 hospitals, including leading oncology centers.
LinkDoc’s ecosystem includes subsidiaries such as Shuyu Medical, which focuses on digital therapeutics and patient management. In September 2020, Linkdoc Technology (Beijing) Co. , Ltd. raised CNY 700 million from new investors CBC Capital, CICC Capital Management, IFOF, and Youshan Capital.
Current Investors
Him Group, Everest VC, Wisdomont Capital
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT
Website
www.linkdoc.com
Verticals
HealthTech, Mobile Apps
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.